Phoenix Life Sciences International Limited.
Healthcare · Medicinal Chemicals & Botanical Products · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $18,410 | $23,549 | $0 |
| Operating income | −$3.1M | −$458 | −$35,811 | −$497,217 | −$2.4M | — |
| Net income | −$3.1M | −$76,590 | −$254,710 | −$787,819 | −$17.4M | −$54,547 |
| Total assets | $11.4M | $236,449 | $236,907 | $256,943 | $1.6M | $6,104 |
| Total liabilities | $1.3M | $1.6M | $1.6M | $1.4M | $2.0M | $10,436 |
| Equity | $10.1M | −$1.4M | −$1.4M | −$1.1M | −$422,266 | −$4,332 |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 32.6M | 34,171 | 31,067 | 25,845 | 423.9M | 89.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- —
- Net margin
- —
- Return on equity
- −30.9%
- Return on assets
- −27.3%
- Return on capital (ROCE)
- −30.4%
- Liabilities / assets
- 11.8%
- Debt / equity
- 0.13×
- Book value / share
- $0.31
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -0.20distress
- Accruals / assets
- −19.7%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗May 31, 2019
- NT 10-Qmissed a reporting deadline ↗Jan 14, 2016
- NT 10-Qmissed a reporting deadline ↗Oct 15, 2015
- NT 10-Qmissed a reporting deadline ↗Jul 14, 2015
- NT 10-Kmissed a reporting deadline ↗May 27, 2015
- NT 10-Qmissed a reporting deadline ↗Jan 13, 2015
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Results of operations · Prior financials not reliable (restatement) · Director / officer change · Shareholder voteNov 20, 2020
- Unregistered equity sale · Director / officer change · Regulation FD disclosure · Other material eventAug 29, 2019
- Director / officer changeAug 9, 2019
- Director / officer change · Regulation FD disclosureJul 11, 2019
- Director / officer changeJun 28, 2019
- Entered a material agreement · Regulation FD disclosureJun 11, 2019
- Regulation FD disclosureDec 10, 2018
- Regulation FD disclosureNov 23, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- REVOKEDNov 16, 2023
- 8-KPHOENIX LIFE SCIENCES INTERNATIONAL LIMITED. (FORM: 8-K, RECEIVED: 08/29/2019 16Nov 20, 2020
- 10-KFORM 10-K ANNUAL REPORTApr 10, 2020
- 8-KCURRENT REPORTAug 29, 2019
- 8-KCURRENT REPORTAug 9, 2019
- 8-KCURRENT REPORTJul 11, 2019
- 8-KCURRENT REPORTJun 28, 2019
- 8-A12GFORM 8-A12GJun 14, 2019
- 8-KCURRENT REPORTJun 11, 2019
- NT 10-KNOTICE OF INABILITY TO TIMELY FILEMay 31, 2019
- 10-QQUARTERLY REPORTMay 24, 2019
- DApr 30, 2019
- 10-QQUARTERLY REPORTApr 25, 2019
- 10-QQUARTERLY REPORTApr 25, 2019
- 10-KANNUAL REPORTApr 22, 2019